Relaxin/insulin-like family peptide receptor 3 (RXFP3) belongs to class A G protein-coupled receptor family. RXFP3 and its endogenous ligand relaxin-3 are mainly expressed in the brain with important roles in the regulation of appetite, energy metabolism, endocrine homeostasis and emotional processing. It is therefore implicated as a potential target for treatment of various central nervous system diseases. Since selective agonists of RXFP3 are restricted to relaxin-3 and its analogs, we conducted a high-throughput screening campaign against 32,021 synthetic and natural product-derived compounds using a cyclic adenosine monophosphate (cAMP) measurement-based method. Only one compound, WNN0109-C011, was identified following primary screening, secondary screening and dose-response studies. Although displayed agonistic effect in cells overexpressing the human RXFP3, it also showed cross-reactivity with the human RXFP4. This hit compound may provide not only a chemical probe to investigate the function of RXFP3/4, but also a novel scaffold for the development of RXFP3/4 agonists.
High-Throughput Screening Campaign Identified a Potential Small Molecule RXFP3/4 Agonist
Guang-yao Lin,Yang Feng,Xiao-qing Cai,Cai-hong Zhou,Lijun Shao,Yan Chen,Linhai Chen,Qing Liu,Qingtong Zhou,R. Bathgate,Dehua Yang,Ming-Wei Wang
Published 2021 in Molecules
ABSTRACT
PUBLICATION RECORD
- Publication year
2021
- Venue
Molecules
- Publication date
2021-12-01
- Fields of study
Medicine, Chemistry
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-54 of 54 references · Page 1 of 1
CITED BY
Showing 1-9 of 9 citing papers · Page 1 of 1